Cargando…
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced inc...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382482/ https://www.ncbi.nlm.nih.gov/pubmed/32709909 http://dx.doi.org/10.1038/s41467-020-17703-6 |
| _version_ | 1783563250649006080 |
|---|---|
| author | Simon, David Tascilar, Koray Krönke, Gerhard Kleyer, Arnd Zaiss, Mario M. Heppt, Franz Meder, Christine Atreya, Raja Klenske, Entcho Dietrich, Peter Abdullah, Abdullah Kliem, Thorsten Corte, Giulia Morf, Harriet Leppkes, Moritz Kremer, Andreas E. Ramming, Andreas Pachowsky, Milena Schuch, Florian Ronneberger, Monika Kleinert, Stefan Maier, Clara Hueber, Axel J. Manger, Karin Manger, Bernhard Berking, Carola Tenbusch, Matthias Überla, Klaus Sticherling, Michael Neurath, Markus F. Schett, Georg |
| author_facet | Simon, David Tascilar, Koray Krönke, Gerhard Kleyer, Arnd Zaiss, Mario M. Heppt, Franz Meder, Christine Atreya, Raja Klenske, Entcho Dietrich, Peter Abdullah, Abdullah Kliem, Thorsten Corte, Giulia Morf, Harriet Leppkes, Moritz Kremer, Andreas E. Ramming, Andreas Pachowsky, Milena Schuch, Florian Ronneberger, Monika Kleinert, Stefan Maier, Clara Hueber, Axel J. Manger, Karin Manger, Bernhard Berking, Carola Tenbusch, Matthias Überla, Klaus Sticherling, Michael Neurath, Markus F. Schett, Georg |
| author_sort | Simon, David |
| collection | PubMed |
| description | Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection. |
| format | Online Article Text |
| id | pubmed-7382482 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73824822020-07-28 Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion Simon, David Tascilar, Koray Krönke, Gerhard Kleyer, Arnd Zaiss, Mario M. Heppt, Franz Meder, Christine Atreya, Raja Klenske, Entcho Dietrich, Peter Abdullah, Abdullah Kliem, Thorsten Corte, Giulia Morf, Harriet Leppkes, Moritz Kremer, Andreas E. Ramming, Andreas Pachowsky, Milena Schuch, Florian Ronneberger, Monika Kleinert, Stefan Maier, Clara Hueber, Axel J. Manger, Karin Manger, Bernhard Berking, Carola Tenbusch, Matthias Überla, Klaus Sticherling, Michael Neurath, Markus F. Schett, Georg Nat Commun Article Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection. Nature Publishing Group UK 2020-07-24 /pmc/articles/PMC7382482/ /pubmed/32709909 http://dx.doi.org/10.1038/s41467-020-17703-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Article Simon, David Tascilar, Koray Krönke, Gerhard Kleyer, Arnd Zaiss, Mario M. Heppt, Franz Meder, Christine Atreya, Raja Klenske, Entcho Dietrich, Peter Abdullah, Abdullah Kliem, Thorsten Corte, Giulia Morf, Harriet Leppkes, Moritz Kremer, Andreas E. Ramming, Andreas Pachowsky, Milena Schuch, Florian Ronneberger, Monika Kleinert, Stefan Maier, Clara Hueber, Axel J. Manger, Karin Manger, Bernhard Berking, Carola Tenbusch, Matthias Überla, Klaus Sticherling, Michael Neurath, Markus F. Schett, Georg Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title | Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_full | Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_fullStr | Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_full_unstemmed | Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_short | Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion |
| title_sort | patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of sars-cov-2 seroconversion |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382482/ https://www.ncbi.nlm.nih.gov/pubmed/32709909 http://dx.doi.org/10.1038/s41467-020-17703-6 |
| work_keys_str_mv | AT simondavid patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT tascilarkoray patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT kronkegerhard patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT kleyerarnd patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT zaissmariom patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT hepptfranz patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT mederchristine patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT atreyaraja patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT klenskeentcho patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT dietrichpeter patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT abdullahabdullah patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT kliemthorsten patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT cortegiulia patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT morfharriet patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT leppkesmoritz patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT kremerandrease patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT rammingandreas patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT pachowskymilena patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT schuchflorian patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT ronnebergermonika patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT kleinertstefan patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT maierclara patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT hueberaxelj patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT mangerkarin patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT mangerbernhard patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT berkingcarola patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT tenbuschmatthias patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT uberlaklaus patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT sticherlingmichael patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT neurathmarkusf patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion AT schettgeorg patientswithimmunemediatedinflammatorydiseasesreceivingcytokineinhibitorshavelowprevalenceofsarscov2seroconversion |